<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04026100</url>
  </required_header>
  <id_info>
    <org_study_id>JSPH-CTA101</org_study_id>
    <nct_id>NCT04026100</nct_id>
  </id_info>
  <brief_title>CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>A Phase I Clinical Trial of CTA101 UCART Cells Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Bioheng Biotech Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, non-randomized and dose-escalation study to evaluate the safety and
      efficacy of CTA101 in relapsed or refractory diffuse large B-cell lymphoma patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity（DLT）</measure>
    <time_frame>Baseline up to 35 days after T cell infusion</time_frame>
    <description>Adverse events assessed according to NCI-CTCAE v4.03 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>4 weeks, 12 weeks, 6 months, 12 months, 18 months and 24 months</time_frame>
    <description>Assessment of overall response rate for weeks 4, 12, months 6, 12, 18 and 24 in accordance with Lugano 2014 (overall response rate，OR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>12 weeks, 6 months, 12 months, 18 months and 24 months</time_frame>
    <description>Assessment of overall response rate for weeks 12, months 6, 12, 18 and 24 in accordance with Lugano 2014（disease control rate，DCR)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>CTA101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTA101</intervention_name>
    <description>Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses. Subjects will been distributed into low dose (0.2×10^6), medium dose (2×10^6), and high dose (3×10^6).</description>
    <arm_group_label>CTA101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed diagnosis of DLBCL per WHO Classification Criteria for
             Lymphocytic Tumors 2016, including DLBCL and PMBCL transformed from follicular
             lymphoma;

          2. Relapsed or refractory DLBCL (meeting one of the following conditions):

               1. Recurrence, progression or stable disease (SD) after treatment with second-line
                  or above second-line chemotherapy regimens;

               2. Recurrence or progression after autologous hematopoietic stem cell
                  transplantation;

          3. At least one measurable lesion must be ≥ 1.5cm in the longest diameter;

          4. Male or female aged 18-70 years;

          5. Estimated survival time ≥ 12 weeks;

          6. Serum albumin ≥ 30g/L, total bilirubin ≤ 25.7umol/L, creatinine ≤ 132.6umol/L, alanine
             transaminase (ALT) and aspartate aminotransferase (AST) &lt;3 times of upper limit of
             normal;

          7. Absolute neutrophil count ≥ 1.0*10^9/L, platelet count ≥ 50*10^9/L;

          8. ECOG performance status 0 to 1;

          9. Echocardiographic diagnosis shows left ventricular ejection fraction (LVEF) ≥ 50%;

         10. No active infection in the lungs;

         11. Latest treatment (radiotherapy, chemotherapy, monoclonal antibody therapy or other
             treatment) must have been completed at least 2 weeks prior to screening;

         12. All women of child-bearing potential must have a negative blood or urine pregnancy
             test at screening, and agree to take medically acceptable contraception measures while
             on study treatment;

         13. Patients or their legal guardians volunteer to participate in the study and sign the
             informed consent.

        Exclusion Criteria:

          1. History of hypersensitivity to any component of cell product;

          2. Prior treatment with any CAR T cell product or other genetically-modified T cell
             therapies;

          3. Recurrence after allogeneic hematopoietic stem cell transplantation;

          4. Patients with severe active infections (excluding simple urinary tract infection and
             bacterial pharyngitis), or currently receiving antibiotic therapy by intravenous drip.
             However, prophylactic antibiotic, antiviral and antifungal treatments are allowed;

          5. HBV DNA copy number detected by PCR in patients with active hepatitis B is &gt; 1000 at
             screening (if HBsAg positive, routine antiviral therapy is required after enrollment),
             as well as CMV, hepatitis C, syphilis and HIV infection;

          6. Patients with New York Heart Associate (NYHA) Class III/IV cardiac insufficiency (see
             Appendix 1);

          7. Patients with Corrected QT interval(QTc)＞450 msecs (Fridericia formula);

          8. Patients with a history of epilepsy;

          9. Intracranial extranodal lesions (tumor cells in cerebrospinal fluid, and/or MRI shows
             intracranial lymphoma invasion);

         10. Extensive invasions of gastrointestinal lymphoma (lesions involving the muscular
             layer, serosa and subserosa, excluding lesions confined to the mucosa and submucosa);

         11. History of other primary cancer, except for the following conditions:

               1. Cured non-melanoma after resection, such as basal cell carcinoma of the skin

               2. Cured carcinoma in situ, such as cervical cancer, bladder cancer or breast cancer

         12. Patients with autoimmune diseases requiring treatment, patients with immunodeficiency
             or requiring immunosuppressive therapy;

         13. Concurrent therapy with systemic steroids within 1 week prior to screening, except for
             the patients recently or currently receiving inhaled steroids;

         14. Women pregnant or lactating, with a pregnancy plan within 6 months, fertile but unable
             to take medically acceptable contraception measures;

         15. Patients who have participated in any other clinical studies within 2 weeks prior to
             screening;

         16. Any situations that the investigator believes may increase the risk of patients or
             interfere with the results of study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianyong Li, Ph.D.</last_name>
    <phone>025-83718836</phone>
    <email>lijianyonglm@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

